Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors

Launched by WUHAN UNION HOSPITAL, CHINA · Feb 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique using a special type of scan called PET (Positron Emission Tomography) to help identify and evaluate certain types of cancer, specifically pancreatic cancer, ovarian cancer, and lung adenocarcinoma. The researchers are using a targeted imaging agent, which is a kind of substance that highlights cancer cells, to improve the accuracy of diagnosing and staging these cancers. They will compare the results of this new imaging method with the standard methods currently used to ensure it is effective in helping doctors understand the size and location of tumors.

To participate in this study, you need to be an adult (18 years or older) and either have a suspected or confirmed diagnosis of one of the cancers mentioned or be a healthy volunteer. You should be in good health and able to comply with the study procedures. Participants will undergo MRI or CT scans to gather information about how the imaging agent works in the body. If you are a woman who can become pregnant, you need to be using contraception during the study. Overall, this trial aims to improve cancer diagnosis and treatment planning while ensuring safety for all participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Each subject must meet all enrollment criteria to be eligible to participate in the study:
• • 1. The subject or his/her legal representative is able to sign and date the informed consent form;
• • 2. A commitment to comply with the research procedures and to cooperate in the implementation of the full research process;
• • 3. Adult patients or healthy volunteers (aged 18 or above) of either sex;
• • 4. Patients with clinically suspected or confirmed malignant tumors such as pancreatic cancer, ovarian cancer, or lung adenocarcinoma (supporting evidence includes serum-related tumor markers, imaging data such as ultrasound, CT, MRI, etc., and histological pathology examination, etc.) and in good general condition;
• • 5. Consistent with the results of specific laboratory tests;
• • 6. Females of childbearing potential who have been using contraception for at least one month prior to screening and who are committed to using contraception for the entire study period and until a specified time after the end of the study；
• • 7. Other set entry criteria.
• Exclusion Criteria:
• * All subjects who meet any of the exclusion criteria baseline will be excluded from the study:
• • 1. Those who are unable to complete a PET/MR or PET/CT examination (including inability to lie down, claustrophobia, radiophobia, etc.);
• • 2. Having other comorbidities;
• • 3. Patients with known hypersensitivity to MSLN antibody fragment developers or synthetic excipients; fasting blood glucose level greater than 11.0 mmol/L prior to 18F-FDG injection；
• • 4. Have a history of comorbid drug use;
• • 5. Patients considered by the investigator to have poor compliance;
• • 6. Patients during pregnancy or lactation;
• • 7. Persons with other factors that make participation in this test inappropriate.